In an endeavour to boost its oncology effort, Merck & Co. has added the first clinical-stage monoclonal antibody to its development pipeline in the form of Agensys' AGS-PSCA, which targets prostate stem cell antigen (PSCA) and is in Phase I development for advanced prostate cancer. This feature considers how the agreement will stand to benefit both parties.